- Home
- ONTO vs MRUS Comparison
ONTO vs MRUS Comparison
Compare ONTO & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONTO
- MRUS
- Stock Information
- Founded
- ONTO 1940
- MRUS 2003
- Country
- ONTO United States
- MRUS Netherlands
- Employees
- ONTO N/A
- MRUS N/A
- Industry
- ONTO Industrial Machinery/Components
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- ONTO Industrials
- MRUS Health Care
- Exchange
- ONTO Nasdaq
- MRUS Nasdaq
- Market Cap
- ONTO 4.9B
- MRUS 5.1B
- IPO Year
- ONTO N/A
- MRUS 2016
- Fundamental
- Price
- ONTO $110.93
- MRUS $69.58
- Analyst Decision
- ONTO Strong Buy
- MRUS Strong Buy
- Analyst Count
- ONTO 7
- MRUS 13
- Target Price
- ONTO $137.86
- MRUS $90.92
- AVG Volume (30 Days)
- ONTO 983.5K
- MRUS 551.1K
- Earning Date
- ONTO 10-30-2025
- MRUS 10-30-2025
- Dividend Yield
- ONTO N/A
- MRUS N/A
- EPS Growth
- ONTO 20.58
- MRUS N/A
- EPS
- ONTO 4.04
- MRUS N/A
- Revenue
- ONTO $1,036,353,000.00
- MRUS $56,228,000.00
- Revenue This Year
- ONTO $3.11
- MRUS $57.42
- Revenue Next Year
- ONTO $11.98
- MRUS $0.23
- P/E Ratio
- ONTO $27.54
- MRUS N/A
- Revenue Growth
- ONTO 15.51
- MRUS 59.77
- 52 Week Low
- ONTO $85.88
- MRUS $33.19
- 52 Week High
- ONTO $228.42
- MRUS $70.65
- Technical
- Relative Strength Index (RSI)
- ONTO 62.05
- MRUS 62.18
- Support Level
- ONTO $102.91
- MRUS $65.74
- Resistance Level
- ONTO $105.35
- MRUS $70.65
- Average True Range (ATR)
- ONTO 2.73
- MRUS 2.41
- MACD
- ONTO 0.12
- MRUS 0.10
- Stochastic Oscillator
- ONTO 85.31
- MRUS 86.40
About ONTO Onto Innovation Inc.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.